Skip to main content

Alnylam Releases Positive Top-line Data on Subcutaneous TTR Amyloidosis Drug

Premium

Alnylam Pharmaceuticals this week reported top-line results from an ongoing phase I trial of its subcutaneously administered TTR-mediated amyloidosis treatment ALN-TTRsc, which showed the drug could knock down serum levels of its target protein by more than 80 percent..

The release of the data come about a week after Alnylam presented positive phase II data on an intravenous version of the drug called ALN-TTR02 (GSN 7/3/2013).

ATTR is caused by mutations in the TTR gene, which triggers accumulation of abnormal amyloid proteins in the body. ALN-TTRsc comprises siRNAs designed to inhibit both the wild-type and mutant forms of the protein, and is formulated with Alnylam's proprietary GalNAc conjugate technology.

The ongoing phase I trial is designed to test ALN-TTRsc in up to 40 healthy individuals, who receive single or multiple ascending subcutaneous doses ranging from 1.25 mg/kg to 10 mg/kg. Primary objectives of the study are safety and tolerability, and secondary objectives include assessment of clinical activity as measured by serum TTR levels.

Assuming positive final results from the study, Alnylam anticipates starting a phase II trial in ATTR patients with familial amyloidotic cardiomyopathy – one of the manifestations of the disease – later this year. Phase III testing could begin as soon as 2014.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.